Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002064 · ClinicalTrials.gov registry record · NA

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

A NA study of HIV Infections and Toxoplasmosis, Cerebral, sponsored by Palo Alto Medical Foundation.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002064: Completed NA study of HIV Infections and Toxoplasmosis, Cerebral, sponsored by Palo Alto Medical Foundation.

NCT00002064 is a NA study of HIV Infections and Toxoplasmosis, Cerebral that has completed, run by Palo Alto Medical Foundation. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002064, a NA study of HIV Infections and Toxoplasmosis, Cerebral, has completed, sponsored by Palo Alto Medical Foundation.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

Conditions Studied

HIV Infections Toxoplasmosis, Cerebral

Interventions

  • DRUG Pyrimethamine
  • DRUG Clindamycin

Study Locations (1)

California

  • Palo Alto Med Foundation - Palo Alto

Trial Details

FieldValue
Phase NA
Palo Alto Medical Foundation

11 total trials

What the finished NCT00002064 record still lists

NCT00002064 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Pyrimethamine is the first listed.

NCT00002064 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00002064 about?

NCT00002064 is a clinical study titled "Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse". To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

What is the current status of trial NCT00002064?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002064 study?

This clinical trial studies the following conditions: HIV Infections, Toxoplasmosis, Cerebral.

What interventions are being tested in trial NCT00002064?

The interventions under investigation include: Pyrimethamine (DRUG), Clindamycin (DRUG).

Who is sponsoring clinical trial NCT00002064?

This trial is sponsored by Palo Alto Medical Foundation, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002064 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002064, the US trial registry maintained by the National Library of Medicine. NCT00002064 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.